Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality

BACKGROUND: The US Food and Drug Administration authorized COVID-19 convalescent plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and the Emergency Use Authorization (EUA), leading to use in about 500,000 patients during the first year of the pandemic for...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:eLife
Autors principals: Casadevall, Arturo, Dragotakes, Quigly, Johnson, Patrick W, Senefeld, Jonathon W, Klassen, Stephen A, Wright, R Scott, Joyner, Michael J, Paneth, Nigel, Carter, Rickey E
Format: Artigo
Idioma:Inglês
Publicat: eLife Sciences Publications, Ltd 2021
Matèries:
Epidemiology and Global Health
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8205484/
https://ncbi.nlm.nih.gov/pubmed/34085928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.69866
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars